Recent Progress in Lyme Disease and Remaining Challenges

Jason R. Bobe, Brandon L. Jutras, Elizabeth J. Horn, Monica E. Embers, Allison Bailey, Robert L. Moritz, Ying Zhang, Mark J. Soloski, Richard S. Ostfeld, Richard T. Marconi, John Aucott, Avi Ma'ayan, Felicia Keesing, Kim Lewis, Choukri Ben Mamoun, Alison W. Rebman, Mecaila E. McClune, Edward B. Breitschwerdt, Panga Jaipal Reddy, Ricardo MaggiFrank Yang, Bennett Nemser, Aydogan Ozcan, Omai Garner, Dino Di Carlo, Zachary Ballard, Hyou Arm Joung, Albert Garcia-Romeu, Roland R. Griffiths, Nicole Baumgarth, Brian A. Fallon

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Lyme disease (also known as Lyme borreliosis) is the most common vector-borne disease in the United States with an estimated 476,000 cases per year. While historically, the long-term impact of Lyme disease on patients has been controversial, mounting evidence supports the idea that a substantial number of patients experience persistent symptoms following treatment. The research community has largely lacked the necessary funding to properly advance the scientific and clinical understanding of the disease, or to develop and evaluate innovative approaches for prevention, diagnosis, and treatment. Given the many outstanding questions raised into the diagnosis, clinical presentation and treatment of Lyme disease, and the underlying molecular mechanisms that trigger persistent disease, there is an urgent need for more support. This review article summarizes progress over the past 5 years in our understanding of Lyme and tick-borne diseases in the United States and highlights remaining challenges.

Original languageEnglish
Article number666554
JournalFrontiers in Medicine
StatePublished - 18 Aug 2021


  • Lyme disease
  • PTLD
  • diagnosis
  • field building
  • pathogenesis
  • prevention
  • treatment
  • vaccine


Dive into the research topics of 'Recent Progress in Lyme Disease and Remaining Challenges'. Together they form a unique fingerprint.

Cite this